A Study of Brepocitinib in Adults With Cutaneous Sarcoidosis
Key facts
- Where
- Melbourne and Parkville, AustraliaSee the 2 sites
- Phase
- Phase 2/3
Where in Australia
- Melbourne, VictoriaHospital not named in the registryContact: Clinical Trial AdministratorTaking people
- Parkville, VictoriaHospital not named in the registryContact: Clinical Trial AdministratorTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Priovant Therapeutics, Inc.
- Trial code
- NCT06978725EU 2026-526437-25-00
- Record updated
- 3 November 2026
- Original description
This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with cutaneous sarcoidosis.Read full original descriptionShow less
A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults With Cutaneous Sarcoidosis
This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with cutaneous sarcoidosis.
Inclusion: Adults subjects; Cutaneous sarcoidosis with characteristic skin biopsy histology; A CSAMI activity score ≥ 10; Weight > 40 kg to < 130 kg, and with a body mass index (BMI) ≤ 45 kg/m2.
Exclusion: History of cancer, with the exception of the following cancers with documentation of complete resection and no evidence of recurrence for ≥ 1 year: basal cell carcinoma, squamous cell carcinoma, or carcinoma in situ of the uterine cervix; High risk of thrombosis or cardiovascular disease; Active or recent infection; High risk of herpes zoster.